このエントリーをはてなブックマークに追加
ID 64370
JaLCDOI
FullText URL
77_1_105.pdf 1.91 MB
Author
Iwasaki, Yoshiaki Health Service Center, Okayama University ORCID Kaken ID publons researchmap
Higuchi, Chigusa Health Service Center, Okayama University
Abstract
The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.
Keywords
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
vaccine
adverse events
antibody response
Amo Type
Case Report
Publication Title
Acta Medica Okayama
Published Date
2023-02
Volume
volume77
Issue
issue1
Publisher
Okayama University Medical School
Start Page
105
End Page
109
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
English
Copyright Holders
Copyright Ⓒ 2023 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT